The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
The age-related decrease in skeletal muscle mass together with the loss of muscle power and function is defined sarcopenia. Mounting evidence suggests that the prevalence of sarcopenia is higher in patients with type 2 diabetes mellitus (T2DM), and different mechanisms may be responsible for this association such as impaired insulin sensitivity, chronic hyperglycemia, advanced glycosylation end products, subclinical inflammation, microvascular and macrovascular complications. Glucose-lowering drugs prescribed for patients with T2DM might impact on these mechanisms leading to harmful or beneficial effect on skeletal muscle. Importantly, beyond their glucose-lowering effects, glucose-lowering drugs may affect per se the equilibrium between protein anabolism and catabolism through several mechanisms involved in skeletal muscle physiology, contributing to sarcopenia. The aim of this narrative review is to provide an update on the effects of glucose-lowering drugs on sarcopenia in individuals with T2DM, focusing on the parameters used to define sarcopenia: muscle strength (evaluated by handgrip strength), muscle quantity/quality (evaluated by appendicular lean mass or skeletal muscle mass and their indexes), and physical performance (evaluated by gait speed or short physical performance battery). Furthermore, we also describe the plausible mechanisms by which glucose-lowering drugs may impact on sarcopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Chen, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Chou, M.-Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.012 · Cited by 7,070 · cited 2×
“Sarcopenia is defined as a syndrome in which muscle mass and muscle function (muscle strength and/or physical performance) progressively decrease with age [5,6].”
BackgroundCruz-Jentoft, A. J., & Sayer, A. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31138-9 · Cited by 3,905
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
SANRA—a scale for the quality assessment of narrative review articles
Baethge, C., Goldbeck-Wood, S., & Mertens, S. (2019) · Research Integrity and Peer Review · doi:10.1186/s41073-019-0064-8 · Cited by 3,469
Goodpaster, B. H., Park, S. W., Harris, T. B., Kritchevsky, S. B., Nevitt, M., Schwartz, A. V., Simonsick, E. M., Tylavsky, F. A., Visser, M., Newman, A. B., et al. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.10.1059 · Cited by 3,083 · cited 1×
“Similarly, a 10–15% loss of leg strength every 10 years has been reported to occur up to 70 years, increasing to 25–40% every 10 years after this age [3].”
BackgroundGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Mechanisms regulating skeletal muscle growth and atrophy
Schiaffino, S., Dyar, K. A., Ciciliot, S., Blaauw, B., & Sandri, M. (2013) · The FEBS Journal · doi:10.1111/febs.12253 · Cited by 1,492 · cited 1×
“AKT also induces the activation of mTOR, which promotes protein synthesis, and inhibits fork head box protein O activity, thus reducing the expression of E3 ubiquitin ligases that mediate the atrophy of muscle cells [104].”
BackgroundThe Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
Research works printed but not linked: 103
- Filippin, 2015, Sarcopenia: A predictor of mortality and the need for early diagnosis and intervention, Aging Clin. Exp. Res., 27, 249, 10.1007/s40520-014-0281-4 · DOI
- Kera, 2019, Defnition of respiratory sarcopenia with peak expiratory fow rate, J. Am. Med. Direct. Assoc., 20, 1021, 10.1016/j.jamda.2018.12.013 · DOI
- Nagano, 2021, Respiratory Sarcopenia and Sarcopenic Respiratory Disability: Concepts, Diagnosis, and Treatment, J. Nutr. Health. Aging., 25, 507, 10.1007/s12603-021-1587-5 · DOI · Paper page
- Buchman, 2008, Pulmonary function, muscle strength and mortality in old age, Mech. Ageing. Dev., 129, 625, 10.1016/j.mad.2008.07.003 · DOI · Paper page
- Okazaki, 2020, Association between sarcopenia and pneumonia in older people, Geriatr. Gerontol. Int., 20, 7, 10.1111/ggi.13839 · DOI · Paper page
- Kwak, 2021, Frailty: Past, present, and future?, SMHS, 3, 1
- Dennison, 2017, Epidemiology of sarcopenia and insight into possible therapeutic targets, Nat. Rev. Rheumatol., 13, 340, 10.1038/nrrheum.2017.60 · DOI · Paper page
- Pourmotabbed, 2020, Sleep duration and sarcopenia risk: A systematic review and dose-response meta-analysis, Sleep Breath, 24, 1267, 10.1007/s11325-019-01965-6 · DOI
- Prokopidis, 2021, Effects of sleep deprivation on sarcopenia and obesity: A narrative review of randomized controlled and crossover trials, J. Frailty Sarcopenia Falls, 6, 50, 10.22540/JFSF-06-050 · DOI
- Steffl, 2016, Alcohol consumption as a risk factor for sarcopenia—a meta-analysis, BMC Geriatr., 16, 16, 10.1186/s12877-016-0270-x · DOI
- Steffl, 2015, Relation between cigarette smoking and sarcopenia: Meta-analysis, Physiol. Res., 64, 419, 10.33549/physiolres.932802 · DOI · Paper page
- Lee, 2007, Associated factors and health impact of sarcopenia in older Chinese men and women: A cross-sectional study, Gerontology, 53, 404, 10.1159/000107355 · DOI · Paper page
- Guillet, 2004, Whole body protein breakdown is less inhibited by insulin, but still responsive to amino acid, in nondiabetic elderly subjects, J. Clin. Endocrinol. Metab., 89, 6017, 10.1210/jc.2003-031323 · DOI · Paper page
- Priego, 2018, Hormones and Muscle Atrophy, Adv. Exp. Med. Biol., 1088, 207, 10.1007/978-981-13-1435-3_9 · DOI
- Carter, 2019, Lipotoxicity, aging, and muscle contractility: Does fiber type matter?, GeroScience, 41, 297, 10.1007/s11357-019-00077-z · DOI · Paper page
- Tuttle, 2020, Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis, Ageing Res. Rev., 64, 101185, 10.1016/j.arr.2020.101185 · DOI · Paper page
- McCormick, 2018, Age-related changes in skeletal muscle: Changes to life-style as a therapy, Biogerontology, 19, 519, 10.1007/s10522-018-9775-3 · DOI · Paper page
- American Diabetes Association (2020). 12. Older Adults: Standards of Medical Care in Diabetes. Diabetes Care, 43, S152–S162. · DOI · Paper page
- Anagnostis, 2020, Type 2 Diabetes Mellitus is Associated with Increased Risk of Sarcopenia: A Systematic Review and Meta-analysis, Calcif Tissue Int., 107, 453, 10.1007/s00223-020-00742-y · DOI · Paper page
- Izzo, A., Massimino, E., Riccardi, G., and Della Pepa, G. (2021). A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. Nutrients, 13. · DOI · Paper page
- Veronese, 2019, Effect of nutritional supplementations on physical performance and muscle strength parameters in older people: A systematic review and meta-analysis, Ageing Res. Rev., 51, 48, 10.1016/j.arr.2019.02.005 · DOI · Paper page
- Dodds, R.M., Syddall, H.E., Cooper, R., Benzeval, M., Deary, I.J., Dennison, E.M., Der, G., Gale, C.R., Inskip, H.M., and Jagger, C. (2014). Grip strength across the life course: Normative data from twelve British studies. PLoS ONE, 9. · DOI · Paper page
- Lee, 2018, Physical Activity and Sarcopenia in the Geriatric Population: A Systematic Review, J. Am. Med. Dir. Assoc., 19, 378, 10.1016/j.jamda.2018.02.003 · DOI · Paper page
- Shaw, 2017, Epidemiology of Sarcopenia: Determinants Throughout the Lifecourse, Calcif. Tissue Int., 101, 229, 10.1007/s00223-017-0277-0 · DOI · Paper page
- Steffl, 2017, Relationship between sarcopenia and physical activity in older people: A systematic review and meta-analysis, Clin. Interv. Aging, 12, 835, 10.2147/CIA.S132940 · DOI · Paper page
- McKendry, J., Currier, B.S., Lim, C., Mcleod, J.C., Thomas, A., and Phillips, S.M. (2020). Nutritional Supplements to Support Resistance Exercise in Countering the Sarcopenia of Aging. Nutrients, 12. · DOI · Paper page
- Bloom, I., Shand, C., Cooper, C., Robinson, S., and Baird, J. (2018). Diet Quality and Sarcopenia in Older Adults: A Systematic Review. Nutrients, 10. · DOI · Paper page
- Robinson, 2018, ESCEO working group. Does nutrition play a role in the prevention and management of sarcopenia?, Clin. Nutr., 37, 1121, 10.1016/j.clnu.2017.08.016 · DOI · Paper page
- Lee, 2020, The Right Diabetes Medication for the Right Patient for the Right Outcome: Can a Network Meta-analysis Help Us Decide?, Ann. Intern. Med., 173, 311, 10.7326/M20-4266 · DOI
- Mosenzon, 2021, From glucose lowering agents to disease/diabetes modifying drugs: A "SIMPLE" approach for the treatment of type 2 diabetes, Cardiovasc. Diabetol, 20, 92, 10.1186/s12933-021-01281-y · DOI
- Patti, A.M., Rizvi, A.A., Giglio, R.V., Stoian, A.P., Ligi, D., and Mannello, F. (2020). Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. J. Clin. Med., 9. · DOI · Paper page
- Beaudart, 2016, Sarcopenia in daily practice: Assessment and management, BMC Geriatr., 16, 170, 10.1186/s12877-016-0349-4 · DOI · Paper page
- Rossi, 2014, Identifying sarcopenia in acute care setting patients, J. Am. Med. Dir. Assoc., 15, e7, 10.1016/j.jamda.2013.11.018 · DOI
- Maggio, M., Ceda, G.P., Ticinesi, A., De Vita, F., Gelmini, G., Costantino, C., Meschi, T., Kressig, R.W., Cesari, M., and Fabi, M. (2016). Instrumental and Non-Instrumental Evaluation of 4-Meter Walking Speed in Older Individuals. PLoS ONE, 11. · DOI · Paper page
- Podsiadlo, 1991, The timed “Up & Go”: A test of basic functional mobility for frail elderly persons, J. Am. Geriatr. Soc., 39, 142, 10.1111/j.1532-5415.1991.tb01616.x · DOI · Paper page
- Bouchi, 2017, Sarcopenia is associated with incident albuminuria in patients with type 2 diabetes: A retrospective observational study, J. Diabetes Investig., 8, 783, 10.1111/jdi.12636 · DOI
- Cui, 2020, A cross-sectional study: Associations between sarcopenia and clinical characteristics of patients with type 2 diabetes, Medicine, 99, e18708, 10.1097/MD.0000000000018708 · DOI
- Fukuoka, 2019, Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients, J. Diabetes Investig., 10, 322, 10.1111/jdi.12908 · DOI · Paper page
- Yang, 2016, Sarcopenia associated with renal function in the patients with type 2 diabetes, Diabetes Res. Clin. Pract., 118, 121, 10.1016/j.diabres.2016.06.023 · DOI
- Aghili, 2014, Body composition in adults with newly diagnosed type 2 diabetes: Effects of metformin, J. Diabetes Metab. Disord., 13, 88, 10.1186/s40200-014-0088-z · DOI · Paper page
- Sexton, 2014, Respiratory effects of insulin sensitisation with metformin: A prospective observational study, COPD, 11, 133, 10.3109/15412555.2013.808614 · DOI
- Koshizaka, 2021, Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study, Diabetes Ther., 12, 183, 10.1007/s13300-020-00949-0 · DOI
- Ishii, 2020, Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients with Type 2 Diabetes, J. Clin. Med. Res., 12, 122, 10.14740/jocmr4078 · DOI
- Yajima, 2018, The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis, J. Diabetes Complications, 32, 759, 10.1016/j.jdiacomp.2018.05.018 · DOI · Paper page
- Rondanelli, 2016, Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus, Patient Prefer. Adherence, 10, 407
- Hong, 2016, Effects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic Pulse Wave Velocity of Obese Type 2 Diabetes Mellitus Patients, Endocrinol. Metab., 31, 80, 10.3803/EnM.2016.31.1.80 · DOI · Paper page
- Tsurutani, 2018, Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study, Diabetes Obes. Metab., 20, 2675, 10.1111/dom.13421 · DOI
- Sano, 2016, Increased grip strength with sodium-glucose cotransporter 2, J. Diabetes, 8, 736, 10.1111/1753-0407.12402 · DOI
- Shimizu, 2019, Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease, Diabetes Obes. Metab., 21, 285, 10.1111/dom.13520 · DOI · Paper page
- Sugiyama, 2018, Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes, J. Atheroscler Thromb, 25, 467, 10.5551/jat.40873 · DOI · Paper page
- Yamakage, 2020, Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial, J. Diabetes Investig., 11, 653, 10.1111/jdi.13179 · DOI
- Tobita, 2017, Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study, Curr. Ther. Res. Clin. Exp., 87, 13, 10.1016/j.curtheres.2017.07.002 · DOI · Paper page
- Sasaki, 2019, Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: The Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study, J. Diabetes Investig., 10, 108, 10.1111/jdi.12851 · DOI · Paper page
- Bouchi, 2017, Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: A pilot study, Cardiovasc. Diabetol., 16, 32, 10.1186/s12933-017-0516-8 · DOI · Paper page
- Inoue, 2019, Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease, J. Diabetes Investig., 10, 1004, 10.1111/jdi.12980 · DOI · Paper page
- Inoue, 2019, SUMS-ADDIT-1 Research group. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial, J. Diabetes Investig., 10, 1012, 10.1111/jdi.12985 · DOI
- Yamamoto, 2016, Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy, Endocr. J., 63, 589, 10.1507/endocrj.EJ15-0749 · DOI · Paper page
- Iemitsu, 2019, Efficacy and Safety of Ipragliflozin in Patients with Type 2 Diabetes: ASSIGN-K Study, J. Endocrinol. Metab., 9, 51, 10.14740/jem570 · DOI
- Kato, 2017, Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: Clinical implication of the importance of exercise habits during treatment with ipragliflozin, Diabetol. Int., 8, 275, 10.1007/s13340-017-0307-1 · DOI
- Miyake, 2018, Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease, Open Med., 13, 402, 10.1515/med-2018-0059 · DOI · Paper page
- Matsuba, 2018, Tofogliflozin decreases body fat mass and improves peripheral insulin resistance, Diabetes Obes. Metab., 20, 1311, 10.1111/dom.13211 · DOI
- Laksmi, 2017, Effect of Metformin on Handgrip Strength, Gait Speed, Myostatin Serum Level, and Health-related Quality of Life: A Double Blind Randomized Controlled Trial among Non-diabetic Pre-frail Elderly Patients, Acta. Med. Indones., 49, 118
- Yokota, 2017, Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome, J. Diabetes Investig., 8, 535, 10.1111/jdi.12606 · DOI
- Bastien, 2019, Effect of PPARγ agonist on aerobic exercise capacity in relation to body fat distribution in men with type 2 diabetes mellitus and coronary artery disease: A 1-yr randomized study, Am. J. Physiol. Endocrinol. Metab., 317, E65, 10.1152/ajpendo.00505.2018 · DOI
- Rizzo, 2016, Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors, J. Am. Med. Dir. Assoc., 17, 896, 10.1016/j.jamda.2016.04.016 · DOI
- Cobo, 2016, Impact of frailty in older patients with diabetes mellitus: An overview, Endocrinol. Nutr., 63, 291, 10.1016/j.endonu.2016.01.004 · DOI
- Mesinovic, 2019, Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship, Diabetes Metab. Syndr. Obes., 12, 1057, 10.2147/DMSO.S186600 · DOI · Paper page
- Liccini, 2016, Frailty and Sarcopenia as Predictors of Adverse Health Outcomes in Persons with Diabetes Mellitus, J. Am. Med. Dir. Assoc., 17, 846, 10.1016/j.jamda.2016.07.007 · DOI · Paper page
- Sazlina, S.G., Lee, P.Y., Chan, Y.M., Hamid, M.S., and Tan, N.C. (2020). The prevalence and factors associated with sarcopenia among community living elderly with type 2 diabetes mellitus in primary care clinics in Malaysia. PLoS ONE, 15. · DOI
- Lazarevich, 2020, Sarcopenia, nutritional status and type 2 diabetes mellitus: A cross-sectional study in a group of Mexican women residing in a nursing home, Nutr. Diet., 77, 515, 10.1111/1747-0080.12551 · DOI
- Okamura, 2019, Shortage of energy intake rather than protein intake is associated with sarcopenia in elderly patients with type 2 diabetes: A cross-sectional study of the KAMOGAWA-DM cohort, J. Diabetes, 11, 477, 10.1111/1753-0407.12874 · DOI · Paper page
- Stangl, 2019, Sarcopenia—Endocrinological and Neurological Aspects, Exp. Clin. Endocrinol. Diabetes, 127, 8
- Pereira, 2008, Insulin resistance of protein metabolism in type 2 diabetes, Diabetes, 57, 56, 10.2337/db07-0887 · DOI · Paper page
- Das, 2012, AMP-activated protein kinase stimulates myostatin expression in C2C12 cells, Biochem. Biophys. Res. Commun., 427, 36, 10.1016/j.bbrc.2012.08.138 · DOI
- Kalyani, 2013, Quadriceps strength, quadriceps power, and gait speed in older U.S. adults with diabetes mellitus: Results from the National Health and Nutrition Examination Survey, 1999-2002, J. Am. Geriat.r Soc., 61, 769, 10.1111/jgs.12204 · DOI · Paper page
- Oberbach, 2006, Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes, Diabetes Care, 29, 895, 10.2337/diacare.29.04.06.dc05-1854 · DOI · Paper page
- Nezameddin, 2020, Understanding Sarcopenic Obesity in Terms of Definition and Health Consequences: A Clinical Review, Curr. Diabetes Rev., 16, 957, 10.2174/1573399816666200109091449 · DOI · Paper page
- Haus, 2007, Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle, J. Appl. Physiol., 103, 2068, 10.1152/japplphysiol.00670.2007 · DOI · Paper page
- Mori, 2019, Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes, J. Diabetes Investig., 10, 1332, 10.1111/jdi.13014 · DOI · Paper page
- Ighodaro, 2018, Molecular pathways associated with oxidative stress in diabetes mellitus, Biomed. Pharmacother., 108, 656, 10.1016/j.biopha.2018.09.058 · DOI · Paper page
- Yaribeygi, 2020, Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus, Oxid. Med. Cell. Longev., 2020, 8609213, 10.1155/2020/8609213 · DOI · Paper page
- Zhang, 2020, Oxidative stress and diabetes: Antioxidative strategies, Front Med., 14, 583, 10.1007/s11684-019-0729-1 · DOI · Paper page
- Bellanti, F., Lo Buglio, A., and Vendemiale, G. (2020). Chapter 9-Oxidative stress and sarcopenia. Aging, 95–103. · DOI
- Gupta, 2017, Association Between the Severity of Diabetic Retinopathy and Falls in an Asian Population with Diabetes: The Singapore Epidemiology of Eye Diseases Study, JAMA Ophthalmol., 135, 1410, 10.1001/jamaophthalmol.2017.4983 · DOI
- Fukuda, 2017, Association of diabetic retinopathy with both sarcopenia and muscle quality in patients with type 2 diabetes: A cross-sectional study, BMJ Open Diabetes Res. Care, 5, 1, 10.1136/bmjdrc-2017-000404 · DOI
- Wang, 2014, Mechanisms of muscle wasting in chronic kidney disease, Nat. Rev. Nephrol., 10, 504, 10.1038/nrneph.2014.112 · DOI · Paper page
- Nomura, 2018, Diabetic polyneuropathy is a risk factor for decline of lower extremity strength in patients with type 2 diabetes, J. Diabetes Investig., 9, 186, 10.1111/jdi.12658 · DOI
- Parasoglou, 2017, Declining Skeletal Muscle Function in Diabetic Peripheral Neuropathy, Clin. Ther., 6, 1085, 10.1016/j.clinthera.2017.05.001 · DOI
- Dziubek, 2015, Peripheral arterial disease decreases muscle torque and functional walking capacity in elderly, Maturitas, 81, 480, 10.1016/j.maturitas.2015.06.001 · doi:10.1016/j.maturitas.2015.06.001
- LaMoia, 2021, Cellular and Molecular Mechanisms of Metformin Action, Endocr Rev, 42, 77, 10.1210/endrev/bnaa023 · DOI · Paper page
- Kristensen, 2014, Two weeks of metformin treatment induces AMPK-dependent enhancement of insulin-stimulated glucose uptake in mouse soleus muscle, Am. J. Physiol. Endocrinol. Metab., 306, E1099, 10.1152/ajpendo.00417.2013 · DOI
- Kwon, 2015, Palmitate activates mTOR/p70S6K through AMPK inhibition and hypophosphorylation of raptor in skeletal muscle cells: Reversal by oleate is similar to metformin, Biochimie, 118, 141, 10.1016/j.biochi.2015.09.006 · DOI
- Boushel, 2010, Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes, Diabetes Obes. Metab., 12, 806, 10.1111/j.1463-1326.2010.01237.x · DOI · Paper page
- Coletta, 2009, Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: A randomised trial, Diabetologia, 52, 723, 10.1007/s00125-008-1256-9 · DOI · Paper page
- Zeng, 2020, Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes, Diabetes Ther., 11, 2521, 10.1007/s13300-020-00922-x · DOI
- Gilbert, 2020, GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head, Front Endocrinol., 11, 178, 10.3389/fendo.2020.00178 · DOI · Paper page
- Rizzo, 2012, Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: Role of dipeptidyl peptidase-IV inhibition, Diabetes Care, 35, 2076, 10.2337/dc12-0199 · DOI · Paper page
- Holst, 2014, GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle, Am. J. Physiol. Endocrinol. Metab., 306, E355, 10.1152/ajpendo.00283.2013 · DOI · Paper page
- Yamamoto, K., Amako, M., Yamamoto, Y., Tsuchihara, T., Nukada, H., Yoshihara, Y., Arino, H., Fujita, M., Uenoyama, M., and Tachibana, S. (2013). Therapeutic effect of exendin-4, a long-acting analogue of glucagon-like peptide-1 receptor agonist, on nerve regeneration after the crush nerve injury. Biomed. Res. Int., 315848. · DOI
- Sasaki, 2019, Sarcopenia, frailty circle and treatment with sodium-glucose cotransporter 2 inhibitors, J. Diabetes Investig., 10, 193, 10.1111/jdi.12966 · DOI · Paper page
- Bonnet, 2018, Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease, Diabetes Metab., 44, 457, 10.1016/j.diabet.2018.09.005 · DOI · Paper page
- Esterline, 2018, Mechanisms in endocrinology: SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?, Eur. J. Endocrinol., 178, R113, 10.1530/EJE-17-0832 · DOI · Paper page
- Murphy, 2018, Nutrition and physical activity countermeasures for sarcopenia: Time to get personal?, Nutr. Bull., 43, 374, 10.1111/nbu.12351 · DOI
Cited by
Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia
Memel, Z., Gold, S. L., Pearlman, M., Muratore, A., & Martindale, R. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00649-w · Cited by 63
Omura, T., & Araki, A. (2022) · Geriatrics & Gerontology International · doi:10.1111/ggi.14339 · Cited by 47
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101681 · Cited by 30
Wang, Y., Lan, B., Zhang, S., Mu, Y., Mi, J., Yu, J., Zhan, Q., Luo, B., Lin, F., Teng, J., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01877-4 · Cited by 8
“In addition to lifestyle changes, drugs for T2DM should be considered, which their hypoglycemic effects through different mechanisms affect sarcopenia [11].”
Burns, R. B., Jay, M. R., Thorndike, A. N., & Kanjee, Z. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-01740 · Cited by 2
Metadata
- Authors
- Massimino, E., Izzo, A., Riccardi, G., & Della Pepa, G.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-08-01
- Volume
- 10
- Issue
- 8
- Pages
- 1958
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3192186764
- Cited by
- 102
- References
- 51
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.